title: Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?
abstract: Comparing a group of infants treated with recombinant erythropoietin and iron supplementation to a group of control infants, no difference was observed concerning the transfusion need. The incidence of retinopathy of prematurity was significantly higher in the treated group. These data need to be confirmed in randomized controlled studies.
authors.forename: C
authors.initials: C
authors.lastname: Romagnoli
authors.forename: E
authors.initials: E
authors.lastname: Zecca
authors.forename: F
authors.initials: F
authors.lastname: Gallini
authors.forename: P
authors.initials: P
authors.lastname: Girlando
authors.forename: A A
authors.initials: AA
authors.lastname: Zuppa
mesh_terms: D001803:Blood Transfusion; D004921:Erythropoietin / Q000009:adverse effects*; D005290:Ferric Compounds / Q000009:adverse effects*; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D011994:Recombinant Proteins; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy; D012178:Retinopathy of Prematurity / Q000145:classification / Q000175:diagnosis / Q000209:etiology*; D012720:Severity of Illness Index
chemical_list: D005290:Ferric Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin; D005293:Ferritins; C013276:teferrol